Weekly Digest - Feb 2024
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
CAR-T Digest - August 2020
Weekly Digest - Feb 2024
21 Feb 2024: Mabwell receives IND Approval from FDA for Novel B7-H3 ADC 7MW3711
- The IND application is for advanced malignant solid tumors, and the clinical trial for 7MW3711 has started in China
- ADC 7MW3711 was developed by Mabwell’s next-generation ADC platform IDDC™ and is composed of an innovative antibody molecule, a novel linker, and a novel payload (topoisomerase I inhibitor)
- Mabwell’s IDDC™ platform, featuring core patent technologies like DARfinity™ and IDconnect™, enhances structural homogeneity, quality stability, and pharmacodynamics of ADC products
- Multiple ADC products, including Trop-2 and Nectin-4-targeting targeting ADC, are in clinical development stages, highlighting Mabwell’s commitment to advancing innovative cancer therapies
